SNGX - Why Is This Rare Disease-Focused Soligenix Stock Trading Over 200% Today? | Benzinga
The FDA has cleared Soligenix Inc's (NASDAQ: SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous ulcers in Behçet's disease.
Behçet disease is a rare vasculitic disorder that can affect small, medium, and large vessels and is characterized by a triple-symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis.
The ...